Phibro Animal Health Corp
NASDAQ:PAHC
Intrinsic Value
Phibro Animal Health Corp. engages in the manufacture and supply of animal health and mineral nutrition products. [ Read More ]
The intrinsic value of one
PAHC
stock under the Base Case scenario is
19.51
USD.
Compared to the current market price of 18.23 USD,
Phibro Animal Health Corp
is
Undervalued by 7%.
Phibro Animal Health Corp's market capitalization is 738.4m USD.
PAHC stock price is 18.23 USD.
PAHC stock price (18.23 USD) is 7% less than its Intrinsic Value (19.51 USD).
PAHC stock price (18.23 USD) is 44% less than its Relative Value (32.63 USD). Open Relative Valuation
PAHC has downside potential of 40% compared to the average analyst price target.
Open Wall St Estimates
PAHC's Revenue has grown by 2% over the past 12 months.
PAHC has positive Free Cash Flow for the last twelve months.
PAHC's Revenue is forecast to grow at a rate of 3% per year over the next 3 years.
PAHC has positive Operating Income for the last twelve months.
PAHC's ROIC (Return on Invested Capital) has decreased in the last 3 years from 7% to 4%.
PAHC's Altman Z-Score is equal to 2.41.
PAHC's ROE (Return on Equity) for the past 12 months is very low and is equal to 5%.
PAHC's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 4%.
PAHC's Revenue has been growing by 8% per year for the last 3 years.
PAHC has positive three-year average ROIC (Return on Invested Capital): 7%. The company is efficient at using invested capital to generate operating income.
PAHC's long-term assets (979m USD) exceed its long-term liabilties (709m USD).
PAHC has positive Net Income for the last twelve months.
PAHC has positive three-year average ROE (Return on Equity): 16%. The company is efficient at transforming stockholders' equity into net income.
PAHC's ROE (Return on Equity) has significantly decreased in the last 3 years from 21% to 5%.
PAHC's D/E (Debt to Equity) is equal to 1.69.
PAHC has positive Gross Profit for the last twelve months.
PAHC has positive Net Debt. This means that the company has more debt (456m USD) than cash and short-term investments (99m USD).
PAHC's short-term assets (597m USD) exceed its short-term liabilties (189m USD).
PAHC generates enough operating income (64m USD) to cover interest payments on its debt (17m USD).
Valuation Backtest
Phibro Animal Health Corp
Run backtest to discover the historical profit from buying and selling
PAHC
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Phibro Animal Health Corp
Balance Sheet Decomposition
Phibro Animal Health Corp
| Current Assets | 597.2m |
| Cash & Short-Term Investments | 98.7m |
| Receivables | 161.1m |
| Other Current Assets | 337.3m |
| Non-Current Assets | 381.9m |
| Long-Term Investments | 11.3m |
| PP&E | 239.2m |
| Intangibles | 102.9m |
| Other Non-Current Assets | 28.6m |
| Current Liabilities | 189.1m |
| Accounts Payable | 82.6m |
| Accrued Liabilities | 44m |
| Other Current Liabilities | 62.5m |
| Non-Current Liabilities | 519.9m |
| Long-Term Debt | 456m |
| Other Non-Current Liabilities | 63.9m |
Earnings Waterfall
Phibro Animal Health Corp
|
Revenue
|
999.5m
USD
|
|
Cost of Revenue
|
-696.3m
USD
|
|
Gross Profit
|
303.1m
USD
|
|
Operating Expenses
|
-239.4m
USD
|
|
Operating Income
|
63.7m
USD
|
|
Other Expenses
|
-50.5m
USD
|
|
Net Income
|
13.2m
USD
|
Free Cash Flow Analysis
Phibro Animal Health Corp
PAHC Profitability Score
Profitability Due Diligence
Phibro Animal Health Corp's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
Score
Phibro Animal Health Corp's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
PAHC Solvency Score
Solvency Due Diligence
Phibro Animal Health Corp's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Score
Phibro Animal Health Corp's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PAHC Price Targets Summary
Phibro Animal Health Corp
According to Wall Street analysts, the average 1-year price target for
PAHC
is 10.97 USD
with a low forecast of 9.09 USD and a high forecast of 13.65 USD.
Ownership
PAHC Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
PAHC Price
Phibro Animal Health Corp
| Average Annual Return | -14.2% |
| Standard Deviation of Annual Returns | 16.96% |
| Max Drawdown | -68% |
| Market Capitalization | 745.3m USD |
| Shares Outstanding | 40 500 000 |
| Percentage of Shares Shorted | 4.59% |
Company Profile
Phibro Animal Health Corp
Country
Industry
Market Cap
Dividend Yield
Description
Phibro Animal Health Corp. engages in the manufacture and supply of animal health and mineral nutrition products. The company is headquartered in Teaneck, New Jersey and currently employs 1,725 full-time employees. The company went IPO on 2014-04-11. The firm operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The firm develops, manufactures and markets a range of products for food animals, including poultry, swine, beef and dairy cattle, and aquaculture. The firm sells animal health and mineral nutrition products either directly to integrated poultry, swine and cattle producers or through commercial animal feed manufacturers, wholesalers and distributors. Its Medicated Feed Additives (MFAs) and other business consist of concentrated medicated products, which are administered through animal feeds. The firm's MFAs and other business consists of the production and sale of antibacterials, including Stafac, Terramycin, Neo-Terramycin and Mecadox and anticoccidials, including Nicarb, Aviax, Aviax Plus, Coxistac and amprolium.
Contact
IPO
Employees
Officers
The intrinsic value of one
PAHC
stock under the Base Case scenario is
19.51
USD.
Compared to the current market price of 18.23 USD,
Phibro Animal Health Corp
is
Undervalued by 7%.
You don't have any saved screeners yet
